Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
483.96
-10.65 (-2.15%)
Nov 14, 2024, 4:00 PM EST - Market closed
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
The 24 analysts with 12-month price forecasts for VRTX stock have an average target of 513.58, with a low estimate of 373 and a high estimate of 600. The average target predicts an increase of 6.12% from the current stock price of 483.96.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for VRTX stock from 29 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 9 | 9 | 10 | 11 |
| Buy | 11 | 10 | 9 | 9 | 8 | 8 |
| Hold | 6 | 6 | 7 | 7 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 26 | 25 | 26 | 26 | 28 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $575 | Strong Buy | Initiates | $575 | +18.81% | Nov 14, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Sell Maintains $361 → $408 | Strong Sell | Maintains | $361 → $408 | -15.70% | Nov 6, 2024 |
| Scotiabank | Scotiabank | Hold Maintains $480 → $486 | Hold | Maintains | $480 → $486 | +0.42% | Nov 5, 2024 |
| UBS | UBS | Strong Buy Maintains $562 → $586 | Strong Buy | Maintains | $562 → $586 | +21.08% | Nov 5, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $480 | Buy | Reiterates | $480 | -0.82% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
11.07B
from 9.87B
Increased by 12.20%
Revenue Next Year
11.99B
from 11.07B
Increased by 8.31%
EPS This Year
0.41
from 13.89
Decreased by -97.07%
EPS Next Year
17.77
from 0.41
Increased by 4,273.82%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 11.5B | 14.4B | 16.3B | ||
| Avg | 11.1B | 12.0B | 13.2B | ||
| Low | 10.4B | 11.0B | 11.5B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 16.8% | 30.2% | 35.9% | ||
| Avg | 12.2% | 8.3% | 9.7% | ||
| Low | 5.3% | -0.6% | -3.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.49 | 24.30 | 24.19 | ||
| Avg | 0.41 | 17.77 | 19.96 | ||
| Low | -0.35 | -16.08 | 2.00 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -89.3% | 5,879.7% | 36.1% | ||
| Avg | -97.1% | 4,273.8% | 12.3% | ||
| Low | - | - | -88.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.